围手术期应用重组人红细胞生成素的多中心随机对照研究

目的 观察围手术期贫血患者使用重组人红细胞生成素（rhEPO）对纠正贫血和减少异体输血的临床效果.方法 74例胃肠道肿瘤伴贫血患者,随机分成治疗组A、治疗组B和对照组C,A组患者术前每天皮下注射rhEPO 1万IU,连续4 d,术后第1、3 d分别皮下注射rhEPO 1万IU;B组患者术前7 d始隔天皮下注射rhEPO 1万IU,连续6次;C组患者不给予rhEPO.观察所有患者贫血纠正及异体输血情况.结果 治疗组患者用药后血红蛋白（Hb）、网织红细胞（Ret）及血细胞比容（Hct）水平高于对照组、用药前,术中及术后异体输血少于对照组.B组疗效优于A组.结论 围手术期使用rhEPO对于纠正贫血和减少异体输血是有效的.

Randomized multicentre trial of the influence of recombinant human erythropoietin on the perioperative patients

Purpose To investigate the effect of recombinant human erythropoietin (rhEPO) on perioperative hemoglobin (Hb) concentration and on the rate and volume of blood transfusion in patients undergoing surgery. Methods Seventy-four cases with anemia and gastrointestinal tract tumor were randomly divided into three groups (study group A, study group B and control group C). The patients in group A received subcutaneous rhEPO in dose of 10 000 IU daily for 4 days before operation, and on the first and third day after operation. The patients in group B 7 days before operation began to receive subcutaneous rhEPO in dose of 10 000 IU every two days for 6 times. The Hb concentration, reticulocyte count and hematocrit (Hct) of all patients were evaluated. Results Compared with the control group, patients who received rhEPO had significantly higher level of Hb concentration,reticulocyte count and hematocrit (Hct) and needed fewer blood transfusion perioperatively. The result of group B was more significant. Conclusions Patients benefit from perioperative erythropoietin administration in terms of stimulated erythropoiesis, reduction in the number of blood transfusions.